Q3 FY26 results: revenue dips, losses widen; wind assets sale approved

Revenue declinedNet loss reportedResults View source PDF Explain this filing

MADHAV · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+12.7%Reaction day

₹37.62

prior close

₹42.60

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%+13.2% vs market

Granites & Marbles peers, median of 7sector-1.8%+14.5% vs sector

On the reaction day the stock moved 13.2 pts more than Nifty Microcap 250 and 14.5 pts more than its Granites & Marbles peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.6

10m

+2.8

15m

+3.3

30m

+1.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+12.7-0.5+13.2-1.8+14.5

Next day

+7.4-1.0+8.4-2.7+10.1

-0.6-2.5+1.9-3.5+2.9

-1.7-3.2+1.5-6.2+4.5

+1.0-2.2+3.2-5.4+6.4

+0.9-1.9+2.8-4.2+5.1

+0.8-3.5+4.2-5.2+5.9

15d

-4.3-8.8+4.5-14.9+10.6

-3.0-9.3+6.3-17.6+14.5

-8.3-4.5-3.8-16.8+8.5

-0.2+5.4-5.5-15.0+14.8

UpDownMarket · Nifty Microcap 250Sector · Granites & Marbles peers, median of 7Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Madhav Marbles Q3 FY26 standalone net sales fell to Rs 660.25 lakh from Rs 685.09 lakh YoY. Standalone Q3 swung to a pre-tax loss of Rs 15.34 lakh versus a profit of Rs 75.42 lakh. Consolidated 9-month pre-tax loss widened sharply to Rs 174.47 lakh from Rs 42.63 lakh. Board approved hiking subsidiary Madhav Ashok Ventures capital from Rs 3.60 Cr to Rs 5 Cr, and authorised sale of two wind power generators in Tamil Nadu.

Likely market impact

Weak Q3 with revenue dip and deepening losses may pressure the stock. Asset sale and subsidiary capital infusion point to ongoing restructuring.